Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
暂无分享,去创建一个
F. Saad | H. Scher | C. Sternberg | C. Logothetis | J. Staffurth | P. Mainwaring | N. Vogelzang | Robert J. Jones | K. Fizazi | K. Chi | J. D. de Bono | C. Haqq | S. Harland | A. Molina | S. North | O. Goodman | T. Kheoh | J. H. Li